Combining anthracycline and taxane for early-stage operable breast cancer was more effective than either anthracycline or taxane chemotherapy alone in reducing breast cancer recurrence and death, ...

Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have identified the mechanisms through which anthracyclines, a widely used class of anticancer drugs, damage the hearts of ...

Please provide your email address to receive an email when new articles are posted on . In September 2007, the FDA approved dexrazoxane hydrochloride injection for the treatment of extravasation ...

Please provide your email address to receive an email when new articles are posted on . A decrease in left ventricular ejection fraction to below normal levels occurred more frequently among women ...

Anthracyclines are widely used to treat hematological and solid-tumor cancers, but past research suggests their use may be associated with late cardiac effects, including heart failure, among patients ...

Adding an anthracycline to adjuvant chemotherapy for TOP2A-normal early breast cancer significantly improved disease-free survival (DFS) but not overall survival (OS) at 10 years, and doubled the risk ...

Anthracyclines are a class of chemotherapies effective in treating many forms of cancer, including leukemias, lymphomas and breast cancer. Anthracyclines - such as doxorubicin, frequently used against ...

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib The Children’s Oncology Group AAML0631 ...

The aim of this study was to determine the activity of anthracycline rechallenge using pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC) previously treated with ...

In a recent study published in JAMA, atorvastatin reduced cardiac functional impairment for patients with lymphoma who were treated with anthracyclines. Although many clinical trials and real-world ...

Cancer patients receiving anthracycline-based chemotherapy are at risk to develop life-threatening chronic cardiotoxicity with the pathophysiological mechanism of action not fully understood. Besides ...